| Literature DB >> 33836386 |
Xavier Bosch1, Aina Capdevila2, Ignacio Grafia2, Andrea Ladino2, Pedro J Moreno2, Alfonso López-Soto2.
Abstract
PURPOSE: Patients evaluated in the emergency department (ED) who have concerning symptoms suggestive of a cancer diagnosis are mostly referred to the quick diagnosis unit of our tertiary hospital. This study analyzed the impact of the Covid-19 pandemic on the volume, disease patterns, and accessibility to essential investigations of patients with suspected cancer referred by the ED to this unit.Entities:
Keywords: Covid-19; Hospital ambulatory medicine; Pandemic; Quick diagnosis units; Suspected cancer
Year: 2021 PMID: 33836386 PMCID: PMC8016540 DOI: 10.1016/j.ajem.2021.03.087
Source DB: PubMed Journal: Am J Emerg Med ISSN: 0735-6757 Impact factor: 2.469
Fig. 1Flowsheet for the patient selection process.
Fig. 2Smoothing spline model of trends in referrals by the emergency department from January 1 to July 9, 2019.
Fig. 3Smoothing spline model of trends in referrals by the emergency department from January 1 to July 8, 2020.
Fig. 4Trends in weekly referrals from January 1 to July 8, 2020. Linear regression models from weeks 0–8 (prepandemic period) (circles), weeks 9–17 (pandemic period) (squares), and weeks 18–28 (postpandemic period) (triangles).
General characteristics of patients and activity of quick diagnosis unit by study period.
| Characteristic | Prepandemic (Jan 1–Feb 19)a | Pandemic (Feb 26–Apr 22) | Postpandemic (Apr 29–Jul 8)b | |||
|---|---|---|---|---|---|---|
| Referrals ( | Referrals ( | Referrals ( | ||||
| Gender, | 0.040 | 0.047 | 0.113 | |||
| Female | 186 (48.44) | 105 (54.40) | 227 (50.44) | |||
| Male | 198 (51.56) | 88 (45.60) | 223 (49.56) | |||
| Age (years), mean ± SD | 63.6 ± 13.4 | <0.001 | 55.0 ± 14.1 | <0.001 | 62.1 ± 15.0 | 0.157 |
| Age groups (years), | <0.001 | <0.001 | 0.176 | |||
| 18–44 | 31 (8.07) | 50 (25.91) | 42 (9.33) | |||
| 45–65 | 199 (51.82) | 85 (44.04) | 230 (51.11) | |||
| >65 | 154 (40.10) | 58 (30.05) | 178 (39.56) | |||
| Annual income (€), | 0.064 | 0.096 | 0.239 | |||
| >100,000 | 5 (1.30) | 3 (1.55) | 6 (1.33) | |||
| 18,000–100,000 | 156 (40.63) | 87 (45.08) | 188 (41.78) | |||
| <18,000 | 223 (58.07) | 103 (53.37) | 256 (56.89) | |||
| Wait time to first appointment (days), mean ± SD | 2.75 ± 1.44 | <0.001 | 6.55 ± 2.18 | <0.001 | 4.26 ± 1.72 | <0.001 |
| Visits to quick diagnosis unit, mean ± SD | 3.04 ± 1.08 | 0.029 | 2.68 ± 0.84 | <0.001 | 3.14 ± 1.23 | 0.185 |
| Total number of visits, | 0.043 | <0.001 | 0.221 | |||
| ≤2 | 222 (57.81) | 122 (63.21) | 252 (56.00) | |||
| ≥3 | 162 (42.19) | 71 (36.79) | 198 (44.00) | |||
| Ratio of successive/first visits, mean ± SD | 1.75 ± 0.44 | 0.038 | 1.53 ± 0.32 | <0.001 | 1.83 ± 0.70 | 0.196 |
| Time-to-diagnosis (days), mean ± SD | 8.33 ± 3.94 | <0.001 | 19.72 ± 10.37 | <0.001 | 13.49 ± 6.45 | <0.001 |
According to the administrative healthcare database of the Health Department of the Government of Catalonia (Catalan Health Surveillance System [CHSS]).
Diagnostic procedures and times elapsed between requesting and performing them by study period.⁎
| Procedure | Prepandemic (Jan 1–Feb 19) | Pandemic (Feb 26–Apr 22) | Postpandemic (Apr 29–Jul 8) | |||
|---|---|---|---|---|---|---|
| Referrals ( | Referrals ( | Referrals ( | ||||
| CT scan, | 117 (30.47) | <0.001 | 37 (19.17) | <0.001 | 149 (33.11) | 0.114 |
| Wait time (days), mean ± SD | 3.54 ± 1.14 | <0.001 | 13.24 ± 9.33 | <0.001 | 8.67 ± 5.27 | <0.001 |
| MRI, | 13 (3.39) | 0.200 | 3 (1.55) | 0.163 | 18 (4.00) | 0.224 |
| Wait time (days), mean ± SD | 6.27 ± 3.41 | <0.001 | 18.66 ± 10.24 | <0.001 | 10.80 ± 5.99 | <0.001 |
| Ultrasonography, | 89 (23.18) | <0.001 | 26 (13.47) | <0.001 | 113 (25.11) | 0.095 |
| Wait time (days), mean ± SD | 2.53 ± 1.02 | <0.001 | 11.50 ± 8.00 | <0.001 | 6.94 ± 4.51 | <0.001 |
| Gastrointestinal endoscopy and EUS, | 136 (35.42) | <0.001 | 85 (44.04) | <0.001 | 158 (35.11) | 0.490 |
| Wait time (days), mean ± SD | 6.41 ± 4.30 | <0.001 | 15.45 ± 10.47 | <0.001 | 10.64 ± 11.31 | <0.001 |
| 18F-FDG PET/CT, | 9 (2.34) | <0.001 | 20 (10.36) | 0.113 | 32 (7.11) | 0.051 |
| Wait time (days), mean ± SD | 3.93 ± 1.88 | <0.001 | 11.31 ± 6.19 | <0.001 | 5.90 ± 2.48 | 0.050 |
| Bronchoscopy and EBUS, | 13 (3.39) | 0.181 | 4 (2.07) | 0.142 | 19 (4.22) | 0.184 |
| Wait time (days), mean ± SD | 5.37 ± 3.25 | <0.001 | 9.39 ± 4.28 | 0.040 | 7.29 ± 3.82 | 0.060 |
| Bone scintigraphy, | 10 (2.60) | 0.203 | 2 (1.04) | 0.139 | 14 (3.11) | 0.190 |
| Wait time (days), mean ± SD | 3.24 ± 1.46 | <0.001 | 8.62 ± 5.25 | <0.001 | 4.78 ± 2.17 | 0.115 |
| Biopsy & cytology, | 86 (22.40) | <0.001 | 15 (7.77) | <0.001 | 118 (26.22) | 0.072 |
| Wait time (days), mean ± SD | 2.75 ± 0.55 | <0.001 | 5.47 ± 2.34 | 0.012 | 3.41 ± 1.10 | 0.126 |
| Bone marrow aspiration & biopsy, | 14 (3.65) | 0.146 | 3 (1.55) | 0.223 | 12 (2.67) | 0.149 |
| Wait time (days), mean ± SD | 4.11 ± 2.13 | 0.109 | 5.83 ± 3.08 | 0.252 | 5.26 ± 2.91 | 0.142 |
CT scan, computed tomography scan; MRI, magnetic resonance image; EUS, gastrointestinal endoscopic ultrasonography; 18F-FDG PET/CT, positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- d-glucose integrated with computed tomography; EBUS, endobronchial ultrasonography.
Examinations not included are, among others, capsule endoscopy, endoscopic retrograde cholangiopancreatography, virtual colonoscopy, echocardiography, high-resolution esophageal manometry, pulmonary function tests, and electromyography.
Mostly including fine-needle aspiration cytology and surgical biopsy of peripheral lymph nodes and lumps, and CT- or ultrasound-guided biopsy of abnormal areas of tissue and organs.
Clinical reasons for referral to quick diagnosis unit by study period.
| Referral reason, | Prepandemic (Jan 1–Feb 19) | Pandemic (Feb 26–Apr 22) | Postpandemic (Apr 29–Jul 8) | |||
|---|---|---|---|---|---|---|
| Referrals ( | Referrals ( | Referrals ( | ||||
| Unintentional weight loss | 54 (14.06) | 0.024 | 40 (20.73) | <0.001 | 52 (11.56) | 0.129 |
| Severe fatigue | 8 (2.08) | 0.004 | 17 (8.81) | 0.052 | 22 (4.89) | 0.118 |
| Fever of unknown origin | 20 (5.21) | <0.001 | 28 (14.51) | 0.048 | 46 (10.22) | 0.023 |
| Anemia | 83 (21.61) | <0.001 | 14 (7.25) | <0.001 | 65 (14.44) | <0.001 |
| Persistent nausea/appetite loss | 9 (2.34) | 0.219 | 10 (5.18) | 0.065 | 7 (1.56) | 0.227 |
| Change in bowel habit | 37 (9.64) | 0.088 | 26 (13.47) | 0.030 | 38 (8.44) | 0.255 |
| Abdominal pain | 23 (5.99) | 0.212 | 14 (7.25) | 0.113 | 19 (4.22) | 0.221 |
| Rectal bleeding/hematochezia | 34 (8.85) | <0.001 | 3 (1.55) | 0.072 | 21 (4.67) | 0.013 |
| Dysphagia | 6 (1.56) | 0.098 | 10 (5.18) | 0.190 | 16 (3.56) | 0.106 |
| Abnormal laboratory tests | 10 (2.60) | 0.228 | 2 (1.04) | 0.420 | 6 (1.33) | 0.202 |
| Lymphadenopathy or palpable lumps | 31 (8.07) | 0.001 | 4 (2.07) | <0.001 | 43 (9.56) | 0.187 |
| Lung or mediastinal mass | 8 (2.08) | 0.209 | 1 (0.52) | 0.155 | 14 (3.11) | 0.179 |
| Pulmonary infiltrate | 2 (0.52) | 0.460 | 2 (1.04) | 0.326 | 0 (0.00) | 0.312 |
| Abdominal mass | 14 (3.65) | 0.102 | 1 (0.52) | 0.038 | 25 (5.56) | 0.164 |
| Jaundice | 3 (0.78) | 0.316 | 0 (0.00) | 0.249 | 6 (1.33) | 0.296 |
| Ascites | 2 (0.52) | 0.453 | 2 (1.04) | 0.720 | 5 (1.11) | 0.322 |
| Pain (other than abdominal) | 20 (5.21) | 0.140 | 6 (3.11) | 0.063 | 29 (6.44) | 0.138 |
| Dyspnea | 7 (1.82) | 0.088 | 10 (5.18) | 0.695 | 24 (5.33) | 0.091 |
| Peripheral edema | 2 (0.52) | 0.519 | 2 (1.04) | 0.586 | 4 (0.89) | 0.422 |
| Pleural effusion | 10 (2.60) | 0.144 | 1 (0.52) | 0.401 | 5 (1.11) | 0.156 |
| Hematuria | 1 (0.26) | 0.844 | 0 (0.00) | 0.377 | 3 (0.67) | 0.343 |
Distribution of malignant diseases by study period.⁎
| Diagnostic categories | Prepandemic (Jan 1–Feb 19) | Pandemic (Feb 26–Apr 22) | Postpandemic (Apr 29–Jul 8) | |||
|---|---|---|---|---|---|---|
| Referrals ( | Referrals ( | Referrals ( | ||||
| Malignant neoplasms, | 82 (21.35) | <0.001 | 11 (5.70) | <0.001 | 121 (26.89) | 0.004 |
| Pancreatic cancer | 14 (3.65) | 0.117 | 2 (1.04) | 0.082 | 19 (4.22) | 0.190 |
| Lung cancer | 7 (1.82) | 1 (0.52) | 13 (2.89) | |||
| Colorectal cancer | 18 (4.69) | 0.087 | 2 (1.04) | 0.073 | 21 (4.67) | 0.638 |
| Breast cancer | 4 (1.04) | 0 (0.00) | 5 (1.11) | |||
| Ovarian cancer | 6 (1.56) | 1 (0.52) | 9 (2.00) | |||
| Hepatocellular carcinoma | 1 (0.26) | 0 (0.00) | 2 (0.44) | |||
| Renal cell carcinoma | 2 (0.52) | 0 (0.00) | 4 (0.89) | |||
| Prostate cancer | 5 (1.30) | 1 (0.52) | 5 (1.11) | |||
| Mesothelioma | 1 (0.26) | 0 (0.00) | 2 (0.44) | |||
| Head and neck cancer | 2 (0.52) | 1 (0.52) | 3 (0.67) | |||
| Esophageal cancer | 1 (0.26) | 1 (0.52) | 4 (0.89) | |||
| Gastric cancer | 1 (0.26) | 0 (0.00) | 2 (0.44) | |||
| Endometrial and cervical cancer | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Thyroid cancer | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Liposarcoma | 1 (0.26) | 0 (0.00) | 2 (0.44) | |||
| Bone sarcoma | 0 (0.00) | 0 (0.00) | 1 (0.22) | |||
| Neuroendocrine tumor | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Hodgkin and non-Hodgkin lymphoma | 13 (3.39) | 0.143 | 2 (1.04) | 0.072 | 22 (4.89) | 0.169 |
| Multiple myeloma | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Myelodysplastic syndrome | 0 (0.00) | 0 (0.00) | 1 (0.22) | |||
| Cancer of unknown primary site | 2 (0.52) | 0 (0.00) | 2 (0.44) |
According to the International Statistical Classification of Diseases and Related Health Problems (ICD-10 Version: 2019) [22].
Some patients presenting with iron-deficiency anemia were diagnosed with these malignancies (see Table 5).
Distribution of nonmalignant diseases by study period.⁎
| Diagnostic categories | Prepandemic (Jan 1–Feb 19) | Pandemic (Feb 26–Apr 22) | Postpandemic (Apr 29–Jul 8) | |||
|---|---|---|---|---|---|---|
| Referrals ( | Referrals ( | Referrals ( | ||||
| Benign neoplasms, | 17 (4.43) | 0.132 | 4 (2.07) | 0.057 | 27 (6.00) | 0.231 |
| Warthin tumor | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Branchial and thyroglossal cyst | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Intestinal polyp | 7 (1.82) | 2 (1.04) | 8 (1.78) | |||
| Gastric polyp | 1 (0.26) | 0 (0.00) | 3 (0.67) | |||
| Pancreatic benign neoplasm | 1 (0.26) | 0 (0.00) | 2 (0.44) | |||
| Benign lipomatous neoplasm | 2 (0.52) | 1 (0.52) | 4 (0.89) | |||
| Leiomyoma of uterus | 1 (0.26) | 0 (0.00) | 2 (0.44) | |||
| Benign neoplasm of ovary | 1 (0.26) | 0 (0.00) | 2 (0.44) | |||
| Benign neoplasm of thyroid gland | 2 (0.52) | 1 (0.52) | 4 (0.89) | |||
| Hematological disorders, | 17 (4.43) | 0.051 | 0 (0.00) | 0.078 | 17 (3.78) | 0.228 |
| Nutritional iron-deficiency anemia | 4 (1.04) | 0 (0.00) | 5 (1.11) | |||
| Anemia of chronic disease | 6 (1.56) | 0 (0.00) | 4 (0.89) | |||
| Multifactorial anemia | 5 (1.30) | 0 (0.00) | 5 (1.11) | |||
| <0.001 | 0.049 | 0.001 | ||||
| Monoclonal gammopathy of undetermined significance | 2 (0.52) | 0 (0.00) | 3 (0.67) | |||
| Nonspecific lymphadenitis, | 16 (4.17) | 0.162 | 3 (1.55) | 0.139 | 22 (4.89) | 0.212 |
| Gastrointestinal disorders, | 75 (19.53) | <0.001 | 79 (40.93) | <0.001 | 94 (20.89) | 0.134 |
| Inflammatory bowel disease | 2 (0.52) | 1 (0.52) | 1 (0.22) | |||
| Irritable bowel syndrome | 25 (6.51) | <0.001 | 33 (17.10) | <0.001 | 36 (8.00) | 0.142 |
| Gastroesophageal reflux disease with esophagitis | 6 (1.56) | 6 (3.11) | 8 (1.78) | |||
| Achalasia | 2 (0.52) | 1 (0.52) | 4 (0.89) | |||
| Barrett esophagus | 2 (0.52) | 1 (0.52) | 1 (0.22) | |||
| Peptic ulcer | 5 (1.30) | 6 (3.11) | 6 (1.33) | |||
| Gastroduodenitis | 8 (2.08) | 0.045 | 13 (6.74) | 0.039 | 10 (2.22) | 0.375 |
| Chronic atrophic gastritis | 4 (1.04) | 4 (2.07) | 6 (1.33) | |||
| Ischemic colitis | 1 (0.26) | 0 (0.00) | 0 (0.00) | |||
| Diverticulitis | 2 (0.52) | 2 (1.04) | 1 (0.22) | |||
| Angiodysplasia of small intestine and/or colon | 3 (0.78) | 1 (0.52) | 3 (0.67) | |||
| Ulcer of intestine | 2 (0.52) | 1 (0.52) | 1 (0.22) | |||
| Hemorrhoids | 9 (2.34) | 7 (3.63) | 12 (2.67) | |||
| Retroperitoneal fibrosis | 1 (0.26) | 1 (0.52) | 1 (0.22) | |||
| Celiac disease | 2 (0.52) | 1 (0.52) | 2 (0.44) | |||
| Postgastric surgery syndromes | 1 (0.26) | 1 (0.52) | 2 (0.44) | |||
| Liver disorders, | 17 (4.43) | 0.152 | 4 (2.07) | 0.289 | 6 (1.33) | 0.097 |
| Alcoholic liver disease | 3 (0.78) | 1 (0.52) | 1 (0.22) | |||
| Toxic liver disease | 2 (0.52) | 0 (0.00) | 1 (0.22) | |||
| Chronic hepatitis, unspecified | 5 (1.30) | 1 (0.52) | 1 (0.22) | |||
| Liver cirrhosis | 2 (0.52) | 2 (1.04) | 2 (0.44) | |||
| Nonalcoholic steatohepatitis | 4 (1.04) | 0 (0.00) | 1 (0.22) | |||
| Autoimmune hepatitis | 1 (0.26) | 0 (0.00) | 0 (0.00) | |||
| Pancreaticobiliary disorders, | 17 (4.43) | 0.222 | 5 (2.59) | 0.494 | 13 (2.89) | 0.155 |
| Cholelithiasis | 6 (1.56) | 2 (1.04) | 5 (1.11) | |||
| Choledocholithiasis | 2 (0.52) | 0 (0.00) | 2 (0.44) | |||
| Calculus of bile duct with cholangitis | 2 (0.52) | 0 (0.00) | 1 (0.22) | |||
| Cholecystitis | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Acute pancreatitis | 2 (0.52) | 1 (0.52) | 0 (0.00) | |||
| Chronic pancreatitis | 2 (0.52) | 1 (0.52) | 2 (0.44) | |||
| Pseudocyst of pancreas | 1 (0.26) | 1 (0.52) | 1 (0.22) | |||
| Primary biliary cholangitis | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Rheumatic and systemic autoimmune diseases, | 16 (4.17) | 0.167 | 5 (2.59) | 0.703 | 12 (2.67) | 0.148 |
| Rheumatoid arthritis | 2 (0.52) | 0 (0.00) | 2 (0.44) | |||
| Palindromic rheumatism | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Polyarteritis nodosa | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Giant cell arteritis and polymyalgia rheumatica | 4 (1.04) | 1 (0.52) | 2 (0.44) | |||
| Systemic lupus erythematosus | 2 (0.52) | 2 (1.04) | 1 (0.22) | |||
| Dermatopolymyositis | 1 (0.26) | 1 (0.52) | 0 (0.00) | |||
| Sjogren's syndrome | 2 (0.52) | 1 (0.52) | 2 (0.44) | |||
| Cryoglobulinemia | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| ANCA-associated vasculitis | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Diffuse (eosinophilic) fasciitis | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Sarcoidosis, | 3 (0.78) | 0.634 | 1 (0.52) | 0.605 | 0 (0.00) | 0.200 |
| Bone disorders, | 5 (1.30) | 0.285 | 1 (0.52) | 0.422 | 4 (0.89) | 0.271 |
| Osteoporosis with vertebral fracture | 3 (0.78) | 1 (0.52) | 2 (0.44) | |||
| Adult osteomalacia | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Fibrous dysplasia (monostotic) | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Autoinflammatory syndromes, | 1 (0.26) | 0.724 | 0 (0.00) | 0.807 | 1 (0.22) | 0.599 |
| Infectious diseases, | 35 (9.11) | 0.100 | 10 (5.18) | 0.144 | 36 (8.00) | 0.158 |
| Acute viral infections and viral hepatitis | 17 (4.43) | 3 (1.55) | 20 (4.44) | |||
| Acute lower respiratory infection, unspecified | 6 (1.56) | 2 (1.04) | 4 (0.89) | |||
| Intestinal infectious diseases | 4 (1.04) | 2 (1.04) | 4 (0.89) | |||
| Sexually transmitted diseases | 3 (0.78) | 1 (0.52) | 1 (0.22) | |||
| Tuberculosis | 3 (0.78) | 1 (0.52) | 4 (0.89) | |||
| Visceral leishmaniasis | 1 (0.26) | 0 (0.00) | 0 (0.00) | |||
| Herpes simplex and herpes zoster | 1 (0.26) | 0 (0.00) | 2 (0.44) | |||
| Acute/subacute infective endocarditis | 0 (0.00) | 1 (0.52) | 1 (0.22) | |||
| Endocrine disorders, | 14 (3.65) | 0.240 | 5 (2.59) | 0.711 | 11 (2.44) | 0.208 |
| Type 2 and 1 diabetes mellitus (uncontrolled) | 5 (1.30) | 2 (1.04) | 4 (0.89) | |||
| Hyperthyroidism | 3 (0.78) | 1 (0.52) | 2 (0.44) | |||
| Hypothyroidism | 2 (0.52) | 2 (1.04) | 4 (0.89) | |||
| Acute thyroiditis | 2 (0.52) | 0 (0.00) | 1 (0.22) | |||
| Primary hyperparathyroidism | 2 (0.52) | 0 (0.00) | 0 (0.00) | |||
| Respiratory diseases, | 8 (2.08) | 0.874 | 4 (2.07) | 0.451 | 11 (2.44) | 0.230 |
| Pleural effusion, unspecified | 3 (0.78) | 1 (0.52) | 2 (0.44) | |||
| Interstitial pulmonary disease, unspecified | 3 (0.78) | 1 (0.52) | 5 (1.11) | |||
| Chronic obstructive pulmonary disease | 2 (0.52) | 2 (1.04) | 4 (0.89) | |||
| Cardiovascular diseases, | 16 (4.17) | 0.205 | 6 (3.11) | 0.513 | 15 (3.33) | 0.283 |
| Heart failure, unspecified | 4 (1.04) | 2 (1.04) | 4 (0.89) | |||
| Acute idiopathic pericarditis | 3 (0.78) | 1 (0.52) | 2 (0.44) | |||
| Pulmonary embolism | 2 (0.52) | 0 (0.00) | 3 (0.67) | |||
| Cerebral infarction, unspecified | 3 (0.78) | 1 (0.52) | 2 (0.44) | |||
| Lymphedema | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Phlebitis and thrombophlebitis of lower or upper limbs | 1 (0.26) | 2 (1.04) | 2 (0.44) | |||
| Hypotension, unspecified | 2 (0.52) | 0 (0.00) | 1 (0.22) | |||
| Urologic diseases, | 8 (2.08) | 0.268 | 5 (2.59) | 0.139 | 6 (1.33) | 0.202 |
| Urinary tract infection including acute prostatitis | 4 (1.04) | 2 (1.04) | 5 (1.11) | |||
| Hydronephrosis with ureteral obstruction | 2 (0.52) | 1 (0.52) | 0 (0.00) | |||
| Renal colic, unspecified | 2 (0.52) | 2 (1.04) | 1 (0.22) | |||
| Dysfunctional uterine bleeding, | 8 (2.08) | 0.216 | 2 (1.04) | 0.211 | 9 (2.00) | 0.624 |
| Diseases of the nervous system, | 12 (3.13) | 0.304 | 5 (2.59) | 0.266 | 8 (1.78) | 0.160 |
| Migraine and other headache syndromes | 2 (0.52) | 1 (0.52) | 1 (0.22) | |||
| Degenerative disease of nervous system, unspecified | 3 (0.78) | 1 (0.52) | 2 (0.44) | |||
| Sleep disorders, unspecified | 2 (0.52) | 2 (1.04) | 1 (0.22) | |||
| Trigeminal neuralgia and postherpetic neuralgia | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Nerve root and plexus disorder, unspecified | 2 (0.52) | 0 (0.00) | 2 (0.44) | |||
| Mononeuropathy, unspecified | 0 (0.00) | 0 (0.00) | 0 (0.00) | |||
| Polyneuropathy, unspecified | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Myopathy, unspecified | 1 (0.26) | 1 (0.52) | 0 (0.00) | |||
| Fibromyalgia and chronic fatigue syndrome, | 3 (0.78) | 0.694 | 2 (1.04) | 0.558 | 3 (0.67) | 0.503 |
| Mental and behavioral disorders, | 13 (3.39) | <0.001 | 30 (15.54) | <0.001 | 27 (6.00) | 0.119 |
| Anxiety disorder, unspecified | 5 (1.30) | 0.050 | 12 (6.22) | 0.134 | 11 (2.44) | 0.157 |
| Health anxiety/somatic symptom disorder | 1 (0.26) | 0.116 | 8 (4.15) | 0.149 | 7 (1.56) | 0.123 |
| Depression, unspecified | 7 (1.82) | 0.145 | 10 (5.18) | 0.152 | 9 (2.00) | 0.333 |
| Medically unexplained physical symptoms, | 1 (0.26) | 0.028 | 11 (5.70) | 0.048 | 7 (1.56) | 0.120 |
ANCA, antineutrophil cytoplasmic antibodies.
According to the International Statistical Classification of Diseases and Related Health Problems (ICD-10 Version: 2019) [22].
Patients presenting with iron-deficiency anemia were diagnosed with the gastrointestinal disorders and uterine conditions indicated here and in Table 4 and are not included in the final computation of cases.
Distribution of patients in whom an organic disorder was not identified according to the initial referral reason by study period.
| Referral reason | Prepandemic (Jan 1–Feb 19) | Pandemic (Feb 26–Apr 22) | Postpandemic (Apr 29–Jul 8) | |||
|---|---|---|---|---|---|---|
| Undisclosed disorder, | Undisclosed disorder, | Undisclosed disorder, | ||||
| Unintentional weight loss | 8/54 (14.81) | <0.001 | 18/40 (45.00) | <0.001 | 12/52 (23.08) | <0.001 |
| Severe fatigue | 2/8 (25.00) | <0.001 | 11/17 (64.71) | <0.001 | 12/22 (54.55) | <0.001 |
| Fever of unknown origin | 1/20 (5.00) | <0.001 | 7 (25.00) | <0.001 | 5/46 (10.87) | 0.045 |
| Dysphagia | 0/6 (0.00) | <0.001 | 2 (20.00) | <0.001 | 1/16 (6.25) | 0.030 |
| Dyspnea | 0/7 (0.00) | <0.001 | 2 (20.00) | <0.001 | 3/24 (12.50) | <0.001 |
Other than chronic fatigue syndrome.